Shares of Leap Therapeutics Inc (NASDAQ:LPTX) have been assigned an average broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and one has given a strong buy rating to the company.
Analysts have set a 1 year consensus target price of $15.50 for the company and are expecting that the company will post ($0.51) EPS for the current quarter, according to Zacks. Zacks has also assigned Leap Therapeutics an industry rank of 198 out of 265 based on the ratings given to its competitors.
Several research firms have recently weighed in on LPTX. ValuEngine upgraded Leap Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday. Zacks Investment Research upgraded Leap Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Tuesday, January 9th.
Shares of Leap Therapeutics (NASDAQ LPTX) opened at $8.20 on Friday. Leap Therapeutics has a 52-week low of $4.90 and a 52-week high of $9.36. The firm has a market capitalization of $98.34, a price-to-earnings ratio of -2.34 and a beta of 1.10.
An institutional investor recently bought a new position in Leap Therapeutics stock. Sabby Management LLC purchased a new stake in shares of Leap Therapeutics Inc (NASDAQ:LPTX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 89,350 shares of the company’s stock, valued at approximately $558,000. Sabby Management LLC owned 0.72% of Leap Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 3.25% of the company’s stock.
WARNING: This story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/03/23/zacks-analysts-set-15-50-target-price-for-leap-therapeutics-inc-lptx.html.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.